| Title | Thrombolytic therapy for deep vein thrombosis: potential application of plasmin. | | Author(s) | Marder VJ | | Institution | David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1795, USA. vmarder@mednet.ucla.edu | | Source | Thromb Res 2009.:S56-61. | | Abstract | Plasmin is the prototype of a distinct class of "direct-acting" fibrinolytic agents, with biochemical and physiological attributes that are favorable for catheter-delivered thrombolytic therapy. Our studies indicate that plasmin is superior to plasminogen activators for hemostatic safety and thrombolytic efficacy in experimental models, and that plasmin has potential to avoid the bleeding risk that accompanies therapy of deep vein thrombosis with currently-used thrombolytic agents. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, N.I.H., Extramural
| | PubMed ID | 19303506 |
|
